Vertex Pharmaceuticals Inc - Asset Resilience Ratio
Vertex Pharmaceuticals Inc (VRTX) has an Asset Resilience Ratio of 6.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Vertex Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Vertex Pharmaceuticals Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Vertex Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vertex Pharmaceuticals Inc (VRTX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.75 Billion | 6.62% |
| Total Liquid Assets | $1.75 Billion | 6.62% |
Asset Resilience Insights
- Limited Liquidity: Vertex Pharmaceuticals Inc maintains only 6.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vertex Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Vertex Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Vertex Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Vertex Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.83% | $1.52 Billion | $26.14 Billion | -1.04pp |
| 2024-12-31 | 6.86% | $1.55 Billion | $22.53 Billion | +3.13pp |
| 2023-12-31 | 3.74% | $849.20 Million | $22.73 Billion | +2.22pp |
| 2022-12-31 | 1.51% | $274.50 Million | $18.15 Billion | -3.92pp |
| 2021-12-31 | 5.43% | $729.90 Million | $13.43 Billion | -0.27pp |
| 2020-12-31 | 5.71% | $670.70 Million | $11.75 Billion | -2.70pp |
| 2019-12-31 | 8.40% | $698.97 Million | $8.32 Billion | +0.11pp |
| 2018-12-31 | 8.30% | $518.11 Million | $6.25 Billion | -3.64pp |
| 2017-12-31 | 11.94% | $423.25 Million | $3.55 Billion | +3.28pp |
| 2016-12-31 | 8.66% | $250.61 Million | $2.89 Billion | -4.46pp |
| 2015-12-31 | 13.12% | $327.69 Million | $2.50 Billion | -19.49pp |
| 2014-12-31 | 32.61% | $761.85 Million | $2.34 Billion | -6.02pp |
| 2013-12-31 | 38.63% | $895.78 Million | $2.32 Billion | +8.48pp |
| 2012-12-31 | 30.15% | $831.81 Million | $2.76 Billion | +7.75pp |
| 2011-12-31 | 22.39% | $493.60 Million | $2.20 Billion | -23.29pp |
| 2010-12-31 | 45.68% | $788.21 Million | $1.73 Billion | +2.82pp |
| 2009-12-31 | 42.87% | $838.25 Million | $1.96 Billion | -2.31pp |
| 2008-12-31 | 45.18% | $442.99 Million | $980.48 Million | +27.69pp |
| 2007-12-31 | 17.49% | $105.21 Million | $601.48 Million | -35.84pp |
| 2006-12-31 | 53.33% | $491.45 Million | $921.58 Million | +1.76pp |
| 2005-12-31 | 51.57% | $283.11 Million | $549.00 Million | -10.27pp |
| 2004-12-31 | 61.84% | $337.31 Million | $545.45 Million | -5.11pp |
| 2003-12-31 | 66.95% | $485.00 Million | $724.41 Million | +2.36pp |
| 2002-12-31 | 64.59% | $526.89 Million | $815.72 Million | +4.71pp |
| 2001-12-31 | 59.88% | $554.00 Million | $925.13 Million | +51.28pp |
| 2000-12-31 | 8.61% | $66.51 Million | $772.88 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more